Update shared on 05 Nov 2025
Analysts have marginally increased their price target for Fisher & Paykel Healthcare to $36.61. This reflects minor adjustments in company fundamentals and updated discount rate assumptions.
Valuation Changes
- Fair Value, as estimated by analysts, remains unchanged at NZ$36.61 per share.
- The discount rate has risen slightly from 7.47% to 7.58%.
- Revenue growth forecast remains virtually unchanged at 11.54%.
- Net profit margin is stable, holding at approximately 21.22%.
- The future P/E ratio has increased slightly from 44.67x to 44.81x.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.